Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 20, 2015

View Archived Issues

Recardio secures financing to advance dutogliptin in acute myocardial infarction

Three-party collaboration to explore combination of Lynparza and CRLX-101

Ludwig Cancer Research and Cancer Research Institute partner with Targovax

Turing and University of Toledo sign research agreement for Canavan disease

Otonomy begins enrollment in phase III trial of OTO-104 in Meniere's disease

Lilly initiates phase I study of LY-3127804 with ramucirumab for advanced solid tumors

Prima BioMed plans trial combining IMP-321 and immune checkpoint inhibitor

LP-226-A-1 shows efficacy in mouse models of Alzheimer's disease

Head and neck cancer results reported for dovitinib trial in genomically selected patients

Crizotinib increases PFS in previously untreated East Asian patients with NSCLC

Oncolytics Biotech starts phase Ib trial of Reolysin, bortezomib and dexamethasone in MM

LPAR1 antagonist tested in mouse NASH model

OCZ-103: oral pentamidine for alcoholic liver disease

Oncolytic viral immunotherapy HF-10 active in trials in patients with superficial cancers

Oragenics completes pre-IND meeting for OG-253

Aduro Biotech files IND application for ADU-741

Vitae releases topline results from multiple-ascending-dose phase I trial of VTP-43742

AstraZeneca's lung cancer drug Tagrisso available in the U.S.

Merck KGaA completes acquisition of Sigma-Aldrich

Imperial Innovations Group discloses anthrax vaccine

Medicinal Chemistry Pharmaceuticals patents anti-MUC-1 antibody

Rgenix divulges creatine transport inhibitors

Novartis reports TLR7 agonists

AbMax Biotechnology introduces anti-HER2 antibodies

The Catholic University of Korea presents cytokine production inhibitors

Kyprolis approved in E.U. for multiple myeloma

FDA advisory committee votes against MCNA for non-muscle invasive bladder cancer

Orkambi approved in E.U. for cystic fibrosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...